scholarly article | Q13442814 |
P50 | author | Stephen G. Ellis | Q62496584 |
Jeffrey Popma | Q87844791 | ||
Gregg W Stone | Q90754539 | ||
James B Hermiller | Q114304401 | ||
Mark A Turco | Q114304436 | ||
Ronald P Caputo | Q114406348 | ||
James Tift Mann | Q114445140 | ||
P2093 | author name string | David A Cox | |
Mary E Russell | |||
Charles O'Shaughnessy | |||
Joel Greenberg | |||
Patrick Bergin | |||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | coronary artery disease | Q844935 |
P304 | page(s) | 221-31 | |
P577 | publication date | 2004-01-15 | |
P1433 | published in | The New England Journal of Medicine | Q582728 |
P1476 | title | A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease | |
P478 | volume | 350 |
Q45005007 | "Active" endoprosthesis with in situ release of an antimitotic or cytostatic drug: a revolution that cannot do without thought |
Q30356028 | "Do least harm" philosophy may suffice for percutaneous coronary intervention in octogenarians. |
Q51429515 | 32P brachytherapy in the treatment of complex Cypher in-stent restenosis. |
Q57058252 | 40 Years of Percutaneous Coronary Intervention: History and Future Directions |
Q58799803 | 9-year clinical follow-up of patients with ST-segment elevation myocardial infarction with Genous or TAXUS Liberté stents |
Q40119069 | A HUVEC line with a stable expression of the VEGF121 gene to achieve complete endothelialization of blood conduits |
Q34761876 | A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial |
Q36973815 | A cardiologist view of vascular disease in diabetes |
Q45125928 | A comparative analysis of major clinical outcomes using drug-eluting stents versus bare metal stents in diabetic versus nondiabetic patients. |
Q37385456 | A comparison of bare-metal and drug-eluting stents for off-label indications |
Q47161708 | A comparison of the main outcomes from BP-BES and DP-DES at five years of follow-up: A systematic review and meta-analysis |
Q45019905 | A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents |
Q38563035 | A journey from CABG to drug-eluting balloon |
Q92723448 | A novel CD147 inhibitor, SP-8356, reduces neointimal hyperplasia and arterial stiffness in a rat model of partial carotid artery ligation |
Q33677854 | A prospective evaluation of the safety and efficacy of the TAXUS Element paclitaxel-eluting coronary stent system for the treatment of de novo coronary artery lesions: design and statistical methods of the PERSEUS clinical program |
Q35028726 | A prospective, multicenter, post marketing surveillance study to evaluate the safety and effectiveness of the Superia-Sirolimus Eluting Coronary Stent System (SSECSS) implanted during routine clinical practice in India |
Q37329589 | A prospective, randomized comparison of promus everolimus-eluting and TAXUS Liberte paclitaxel-eluting stent systems in patients with coronary artery disease eligible for percutaneous coronary intervention: the PROMISE study |
Q41347740 | A randomized multicenter trial comparing the XIENCE everolimus eluting stent with the CYPHER sirolimus eluting stent in the treatment of female patients with de novo coronary artery lesions: The SPIRIT WOMEN study |
Q40105594 | A randomized, controlled, multicenter trial to evaluate the safety and efficacy of Zotarolimus- vs. Paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries: five-year results from the ZOMAXX I trial |
Q39121911 | A rare and serious unforeseen complication of cutting balloon angioplasty |
Q55424383 | A rare complication of percutaneous coronary intervention: Coronary pseudoaneurysm formation. |
Q37357342 | A review of current devices and a look at new technology: drug-eluting stents |
Q42180347 | Accelerated Recovery of Endothelium Function after Stent Implantation with the Use of a Novel Systemic Nanoparticle Curcumin |
Q46228970 | Acrylic copolymers as candidates for drug-eluting coating of vascular stents |
Q46827359 | Acute thrombosis of a mesenteric artery drug-eluting stent following clopidogrel cessation |
Q90354205 | Additional postdilatation using noncompliant balloons after everolimus-eluting stent implantation: Results of the PRESS trial |
Q36398733 | Adjunctive balloon postdilatation after stent deployment: is it still necessary with drug-eluting stents? |
Q36680683 | Adjunctive pharmacotherapy for coronary interventions-time to read the writing on the wall |
Q58549172 | Advanced Glycation End Products:Receptors for Advanced Glycation End Products Axis in Coronary Stent Restenosis: A Prospective Study |
Q98771885 | Advances in IVUS/OCT and Future Clinical Perspective of Novel Hybrid Catheter System in Coronary Imaging |
Q28181298 | Advances in adjunctive pharmacological therapy for percutaneous coronary interventions |
Q36046070 | Advances in nuclear imaging for preoperative risk assessment |
Q84140501 | Advances in percutaneous coronary intervention |
Q28972437 | Advances in stent technologies and their effect on clinical efficacy and safety |
Q37866105 | Advantages and disadvantages of biodegradable platforms in drug eluting stents |
Q51065281 | Adverse clinical events in patients treated with sirolimus-eluting stents: the impact of Type D personality. |
Q91768223 | An abluminal biodegradable polymer sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients undergoing coronary revascularization: 3-year clinical outcomes of a randomized non-inferiority trial |
Q36086606 | An evidence-based approach to the use of drug-eluting stents in clinical practice |
Q36614126 | An overview of the TAXUS Express, paclitaxel-eluting stent clinical trial program |
Q51192886 | Analysis of location and pattern of target vessel failure in chronic total occlusions after stent implantation and its potential for the efficient use of drug-eluting stents. |
Q50990628 | Angiographic and 3D intravascular ultrasound assessment of overlapping bare metal stent and three different formulations of drug-eluting stents in patients with diabetes mellitus. |
Q37347986 | Angiographic and clinical comparison of novel Orsiro Hybrid sirolimus-eluting stents and Resolute Integrity zotarolimus-eluting stents in all-comers with coronary artery disease (ORIENT trial): study protocol for a randomized controlled trial |
Q53153267 | Angiographic patterns of in-stent restenosis classified by computed tomography in patients with drug-eluting stents: correlation with invasive coronary angiography. |
Q37435155 | Angiographic results of the cobalt chromium Vision and Mini-Vision stents |
Q38118943 | Angioplasty guided by intravascular ultrasound: meta-analysis of randomized clinical trials |
Q28251955 | Angiotensin antagonism in coronary artery disease: results after coronary revascularisation |
Q37664434 | Anti-CD133 antibody immobilized on the surface of stents enhances endothelialization. |
Q37695396 | Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a lipase-cleavable Sn 2 taxane phospholipid prodrug using α(v)β₃-targeted theranostic nanoparticles. |
Q37109628 | Anti-atherosclerotic and anti-diabetic properties of probucol and related compounds |
Q36635049 | Anti-inflammatory effects of arsenic trioxide eluting stents in a porcine coronary model |
Q52593614 | Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma. |
Q93379484 | Antiplatelet agents in uncertain clinical scenarios-a bleeding nightmare |
Q39498712 | Antiplatelet therapy after coronary stenting |
Q28195049 | Antiplatelet therapy after percutaneous coronary intervention |
Q36917389 | Antiplatelet therapy in patients undergoing coronary stenting: The risk of late stent thrombosis |
Q36941850 | Antiplatelet therapy in the era of drug-eluting stents: current and future perspectives |
Q44993846 | Antiproliferative drug-eluting stents: systematic review of the benefits and estimate of economic impact |
Q41989723 | Application of rotational atherectomy in the drug-eluting stent era. |
Q43046506 | Attending to links in the safety chain for drug-eluting stents |
Q37362731 | Avoiding restenosis: is there a role for glucocorticoids in the drug-eluting stent era? |
Q51120123 | BRAVO I: A pilot study of vascular brachytherapy in polytetrafluoroethylene dialysis access grafts. |
Q38036346 | Back to the future: how biology and technology could change the role of PTFE grafts in vascular access management |
Q85555592 | Bare Metal Stents Versus Drug Eluting Stents: Where Do We Stand in 2015? |
Q37502920 | Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis |
Q37906371 | Bare-metal stents versus drug-eluting stents for primary angioplasty: long-term outcome |
Q33833003 | Bayesian design of noninferiority trials for medical devices using historical data |
Q39550187 | Berberine cooperates with adrenal androgen dehydroepiandrosterone sulfate to attenuate PDGF-induced proliferation of vascular smooth muscle cell A7r5 through Skp2 signaling pathway |
Q28576577 | Berberine suppresses MEK/ERK-dependent Egr-1 signaling pathway and inhibits vascular smooth muscle cell regrowth after in vitro mechanical injury |
Q38381158 | Beyond restenosis: Patients' preference for drug eluting or bare metal stents |
Q38059840 | Biodegradable versus durable polymer drug eluting stents in coronary artery disease: insights from a meta-analysis of 5,834 patients. |
Q45964336 | Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trial. |
Q46395870 | Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial |
Q35939015 | Biomimetic actuators: where technology and cell biology merge |
Q39097196 | Bioresorbable Scaffolds for Coronary Artery Disease |
Q28076491 | Bioresorbable Scaffolds: Current Evidences in the Treatment of Coronary Artery Disease |
Q36055029 | Bioresorbable Stents in PCI. |
Q38105546 | Bioresorbable scaffolds in the treatment of coronary artery disease |
Q26766579 | Bioresorbable scaffolds: a new paradigm in percutaneous coronary intervention |
Q27690259 | Bioresorbable scaffolds: rationale, current status, challenges, and future |
Q36040667 | Bisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathies |
Q47296986 | Blinded sample size recalculation in clinical trials with binary composite endpoints |
Q30667055 | Borderline trend towards long-term mortality benefit from drug eluting stents implantation in ST-elevation myocardial infarction patients in Poland-data from NRDES registry. |
Q35291798 | Bridging therapy for early surgery in patients on dual antiplatelet therapy after drug-eluting stent implantation |
Q47381152 | Carbon-coated stents in patients with acute coronary syndromes |
Q51558606 | Cardiac revascularization--a need for independent decision-makers. |
Q55260543 | Cardiovascular Outcomes in Patients on Hemodialysis following Drug-Eluting versus Bare-Metal Coronary Stents. |
Q38381419 | Causes, assessment, and treatment of stent thrombosis--intravascular imaging insights |
Q40388668 | Characterization of Porous TiO2 Surfaces Formed on 316L Stainless Steel by Plasma Electrolytic Oxidation for Stent Applications |
Q39628078 | Choice of stent and outcomes after treatment of drug-eluting stent restenosis in highly complex lesions |
Q38194095 | Choosing the right coronary stent in the modern era. |
Q34981550 | Circulating fibroblast growth factor 23 is associated with angiographic severity and extent of coronary artery disease |
Q33770283 | Clinical Implication of Optical Coherence Tomography-Based Neoatherosclerosis |
Q37647406 | Clinical Outcomes in Diabetic Patients Who Underwent Percutaneous Coronary Intervention during the Plain Old Balloon Angioplasty (POBA)-, Bare Metal Stents (BMS)- and Drug-eluting Stents (DES)-eras from 1984 to 2010. |
Q47131283 | Clinical and Angiographic Outcomes of the First Korean-made Sirolimus-Eluting Coronary Stent with Abluminal Bioresorbable Polymer |
Q43015474 | Clinical and angiographic outcomes of drug-eluting stents in patients with large vessel and single coronary artery lesion. |
Q47791469 | Clinical and angiographic results of angioplasty with a paclitaxel-eluting stent for unprotected left main coronary artery disease (a study of 101 consecutive patients). |
Q33437306 | Clinical effectiveness of coronary stents in elderly persons: results from 262,700 Medicare patients in the American College of Cardiology-National Cardiovascular Data Registry |
Q51809654 | Clinical effects of routine postdilatation of drug-eluting stents. |
Q47778717 | Clinical impact of drug-eluting stents in an unselected population of diabetic patients. |
Q57566896 | Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial |
Q36528924 | Clinical outcomes between different stent designs with the same polymer and drug: comparison between the Taxus Express and Taxus Liberte stents |
Q84326034 | Clinical outcomes for single stent and multiple stents in contemporary practice |
Q36602870 | Clinical outcomes in 995 unselected real-world patients treated with an ultrathin biodegradable polymer-coated sirolimus-eluting stent: 12-month results from the FLEX Registry. |
Q38630250 | Clinical outcomes of biodegradable polymer biolimus-eluting BioMatrix stents versus durable polymer everolimus-eluting Xience stents. |
Q41486927 | Clinical outcomes of real-world patients treated with an amphilimus polymer-free stent versus new generation everolimus-eluting stents. |
Q37388164 | Clinical outcomes with Biolimus (A9)™ eluting stent, 'BioMatrix' in diabetic patients--interim results from multicenter post market surveillance registry in India |
Q46358322 | Clinical results of drug eluting stents compared to bare metal stents for patients with ST elevation acute myocardial infarction |
Q35879094 | Clinical trials in restenosis with 7-hexanoyltaxol and paclitaxel-eluting stents |
Q28219418 | Clinical update on the therapeutic use of clopidogrel: treatment of acute ST-segment elevation myocardial infarction (STEMI) |
Q42623179 | Clinical usefulness of the Driver(®) stent in a retrospective, collaborative, multicenter, open-label study in Japanese real-world patients with coronary artery disease and the drug-eluting stent era. |
Q37209003 | Clopidogrel and coronary stents: risks and benefits |
Q28199126 | Clopidogrel treatment surrounding percutaneous coronary intervention: when should it be started and stopped? |
Q40393685 | Clopidogrel: cardiologists' panacea or neurologists' headache? |
Q30573045 | Clopidogrel: the data, the experience, and the controversies |
Q43179050 | Combined drug release from biodegradable bilayer coating for endovascular stents |
Q39334521 | Combined paclitaxel-eluting balloon and Genous cobalt-chromium alloy stent utilization in de novo coronary stenoses (PEGASUS). |
Q37594516 | Comparative Study between Perfusion Changes and Positive Findings on Coronary Flow Reserve |
Q34888771 | Comparative effectiveness of drug-eluting stents on long-term outcomes in elderly patients treated for in-stent restenosis: a report from the National Cardiovascular Data Registry |
Q46732330 | Comparative endoluminal visualization of TAXUS crush-stenting at 9 months follow-up by intravascular ultrasound and optical coherence tomography |
Q46583403 | Comparative study of tacrolimus and paclitaxel stent coating in the porcine coronary model |
Q28551554 | Comparing the Clinical Outcomes between Drug Eluting Stents and Bare Metal Stents in Patients with Insulin-Treated Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 10 Randomized Controlled Trials |
Q58268606 | Comparing the use of cobalt chromium stents to stainless steel stents in primary percutaneous coronary intervention for acute myocardial infarction: A prospective registry |
Q28468709 | Comparison of Bare-Metal Stent and Drug-Eluting Stent for the Treatment of Patients Undergoing Percutaneous Coronary Intervention for Unprotected Left Main Coronary Artery Disease - Long-Term Result from a Single Center Experience |
Q37590761 | Comparison of Clinical Outcomes in Patients Undergoing Coronary Intervention with Drug-Eluting Stents or Bare-Metal Stents: A Nationwide Population Study. |
Q36992991 | Comparison of Drug-eluting Coronary Stents, Bare Coronary Stents and Self-expanding Stents in Angioplasty of Middle Cerebral Artery Stenoses |
Q39238408 | Comparison of Vascular Responses Following New-Generation Biodegradable and Durable Polymer-Based Drug-Eluting Stent Implantation in an Atherosclerotic Rabbit Iliac Artery Model |
Q36291363 | Comparison of bare-metal stents and drug-eluting stents in coronary ostial lesions (from the National Heart, Lung, and Blood Institute Dynamic Registry). |
Q37466710 | Comparison of coronary DES and BMS in octogenarians: A systematic review and meta-analysis |
Q92977964 | Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis |
Q37588855 | Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial |
Q87403678 | Comparison of first- and second-generation drug-eluting stent efficacies for treating left main and/or three-vessel disease: a propensity matched study |
Q40699215 | Comparison of long-term in-stent vascular response between abluminal groove-filled biodegradable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent: 3-year OCT follow-up from the TARGET I trial |
Q43235841 | Comparison of long-term outcomes following sirolimus-eluting stent vs paclitaxel-eluting stent implantation in patients with long calcified coronary lesions |
Q39717689 | Comparison of long-term outcomes of bare-metal and paclitaxel-eluting stents in New York |
Q37098303 | Comparison of one-year clinical outcomes with paclitaxel-eluting stents versus bare metal stents in everyday practice |
Q35932110 | Comparison of optical coherence tomographic assessment between first- and second-generation drug-eluting stents |
Q28219874 | Comparison of outcomes of percutaneous coronary intervention on proximal versus non-proximal left anterior descending coronary artery, proximal left circumflex, and proximal right coronary artery: a cross-sectional study |
Q37445290 | Comparison of sirolimus and paclitaxel-eluting stents for complex coronary lesions: an intravascular ultrasound study. |
Q53396688 | Comparison of the efficacy and safety of paclitaxel-eluting coroflex please stents and paclitaxel-eluting stents in patients with coronary artery disease: a randomized PIPA trial. |
Q51097849 | Comparison of the slow-release polymer-based paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions. |
Q35831446 | Comparison of zotarolimus- and everolimus-eluting coronary stents: final 5-year report of the RESOLUTE all-comers trial |
Q34431992 | Comparison of zotarolimus-eluting and sirolimus-eluting coronary stents: a study from the Western Denmark Heart Registry |
Q53170857 | Comparisons of everolimus and Paclitaxel-eluting stents in patients with acute myocardial infarction. |
Q36095492 | Complete myocardial revascularization: between myth and reality |
Q37768719 | Computational structural modelling of coronary stent deployment: a review |
Q36495111 | Computerized two-lead resting ECG analysis for the detection of coronary artery stenosis after coronary revascularization |
Q82905497 | Concurrent drug eluting/bare metal stent implantation during percutaneous coronary intervention in target vessel: outcomes and 1-year follow-up |
Q89842792 | Conditional power analysis of the DEBUT trial - Authors' reply |
Q56384060 | Consensus Document ANMCO/ANCE/ARCA/GICR-IACPR/GISE/SICOA: Long-term Antiplatelet Therapy in Patients with Coronary Artery Disease |
Q41994984 | Contact lenses for ophthalmic drug delivery |
Q26795703 | Contact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug delivery |
Q64924246 | Contemporary Use of Drug-eluting Stents. |
Q38591868 | Continuation of Dual-Antiplatelet Therapy Following Percutaneous Revascularization with a Drug-Eluting Stent: What Duration Is Optimal? |
Q38543392 | Controlling drug delivery from coronary stents: are we aiming for the right targets? |
Q38079934 | Controversies in the use & implementation of drug-eluting stent technology. |
Q50944381 | Controversies surrounding the use of drug-eluting stents. |
Q51065465 | Coronary artery bypass surgery versus percutaneous coronary intervention with drug-eluting stent implantation in patients with multivessel coronary disease. |
Q51321265 | Coronary artery calcification as a new predictor of non-target lesion revascularization during the chronic phase after successful percutaneous coronary intervention. |
Q35193488 | Coronary artery disease in type 2 diabetes mellitus: Recent treatment strategies and future perspectives |
Q40693886 | Coronary artery overexpansion increases neointimal hyperplasia after stent placement in a porcine model |
Q36569798 | Coronary artery restenosis: vascular biology and emerging therapeutic strategies |
Q38109113 | Coronary drug-eluting stents: from design optimization to newer strategies |
Q49948954 | Coronary plaque characteristics on baseline CT predict the need for late revascularization in symptomatic patients after percutaneous intervention. |
Q35189881 | Coronary revascularization trends in the United States, 2001-2008. |
Q38009703 | Coronary stent choice in patients with acute myocardial infarction |
Q46920107 | Coronary stent imaging with dual-source CT: assessment of lumen visibility using different convolution kernels and postprocessing filters |
Q53433469 | Coronary stent occlusion: reverse attenuation gradient sign observed at computed tomography angiography improves diagnostic performance. |
Q36514842 | Coronary stent thrombosis: current insights into new drug-eluting stent designs |
Q37121422 | Coronary stent thrombosis: what have we learned? |
Q43250825 | Coronary stenting with the sirolimus-eluting stent in patients with restenosis after intracoronary brachytherapy: results from the prospective multicentre German Cypher Stent Registry |
Q38093501 | Coronary stents: historical development, current status and future directions |
Q46137918 | Correlation between quantitative angiographic and intravascular ultrasound parameters in patients treated with sirolimus analogous-eluting stents |
Q36703074 | Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial |
Q34669846 | Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents in patients with multivessel coronary artery disease compared to coronary artery bypass surgery five-years after intervention. |
Q40375049 | Cost-effectiveness of primary percutaneous coronary intervention versus thrombolytic therapy for acute myocardial infarction |
Q46921049 | Cost-effectiveness of the Taxus paclitaxel-eluting stent in the Swedish healthcare system |
Q38224405 | Current and future perspectives on drug-eluting bioresorbable coronary scaffolds |
Q37125540 | Current status of off-pump coronary artery bypass surgery |
Q37799356 | Current status of the Xience V® everolimus-eluting coronary stent system. |
Q45004986 | Cypher stent: the German registry. Results of the German prospective multicenter registry on Cypher |
Q36335170 | Cypher versus taxus: are there differences? |
Q37749818 | Decision-making: stenting in acute myocardial infarction |
Q44763980 | Decreased risk of stent fracture-related restenosis between paclitaxel-eluting stents and sirolimus eluting stents: results of long-term follow-up |
Q64058860 | Delivery of Cell-Specific Aptamers to the Arterial Wall with an Occlusion Perfusion Catheter |
Q34349030 | Delivery of plasmid DNA to vascular tissue in vivo using catheter balloons coated with polyelectrolyte multilayers |
Q91588188 | Developing and Testing a Personalized, Evidence-Based, Shared Decision-Making Tool for Stent Selection in Percutaneous Coronary Intervention Using a Pre-Post Study Design |
Q37768165 | Development and performance of the zotarolimus-eluting Endeavor coronary stent |
Q36333923 | Diabetes and percutaneous coronary intervention in the setting of an acute coronary syndrome |
Q41608247 | Diagnosis and management challenges of in-stent restenosis in coronary arteries |
Q50979928 | Diagnostic accuracy of 64-slice CT in the assessment of coronary stents. |
Q33551242 | Diagnostic accuracy of 64-slice computed tomography coronary angiography for the detection of in-stent restenosis: a meta-analysis |
Q28552391 | Dialysis Patients with Implanted Drug-Eluting Stents Have Lower Major Cardiac Events and Mortality than Those with Implanted Bare-Metal Stents: A Taiwanese Nationwide Cohort Study |
Q53598172 | Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial. |
Q51355090 | Diphenylalanine peptide nanotubes self-assembled on functionalized metal surfaces for potential application in drug-eluting stent. |
Q36232816 | Direct stenting with sirolimus-eluting stents |
Q24306656 | Disruption of platelet-derived growth factor-dependent phosphatidylinositol 3-kinase and phospholipase Cγ 1 activity abolishes vascular smooth muscle cell proliferation and migration and attenuates neointima formation in vivo |
Q36345131 | Distinctive effects of CD34- and CD133-specific antibody-coated stents on re-endothelialization and in-stent restenosis at the early phase of vascular injury |
Q51520186 | Do drug-eluting stents mark the end of coronary artery bypass surgery? |
Q37941867 | Do statins have a role in reduction/prevention of post-PCI restenosis? |
Q36997203 | Does the use of paclitaxel or rapamycin-eluting stent decrease further need for coronary-artery bypass grafting when compared with bare-metal stent? |
Q51484880 | Dollars and stents: the economics of drug-eluting stents. |
Q36815941 | Drug delivery via nano-, micro and macroporous coronary stent surfaces. |
Q36812894 | Drug eluting stents for ST-elevation myocardial infarction: risk and benefit |
Q36282710 | Drug eluting stents: an updated meta-analysis of randomised controlled trials |
Q37853958 | Drug eluting versus bare metal stents in cardiac allograft vasculopathy: a systematic review of literature |
Q84982962 | Drug-Eluting Stents Are Not Indicated for Patients With Acute Coronary Syndrome - Should Drug-Eluting Stents Be Indicated for Patients With Acute Coronary Syndrome? (Con) - |
Q92189331 | Drug-coated Balloons for Small Coronary Vessel Interventions: A Literature Review |
Q38241038 | Drug-coated balloon angioplasty for drug-eluting stent restenosis: insight from randomized controlled trials |
Q92781182 | Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial |
Q38028877 | Drug-coated balloons for coronary and peripheral interventional procedures |
Q45057770 | Drug-coated stents. Where do we stand in 2004? |
Q37902075 | Drug-eluting Stents in Acute Coronary Syndrome: Is There a Risk of Stent Thrombosis with Second-Generation Stents? |
Q38818530 | Drug-eluting balloon versus bare-mental stent and drug-eluting stent for de novo coronary artery disease: A systematic review and meta-analysis of 14 randomized controlled trials |
Q38037077 | Drug-eluting coronary stents - focus on improved patient outcomes |
Q48028885 | Drug-eluting coronary stents: as safe as bare-metal stents, but optimized antiplatelet therapy may further improve clinical outcome |
Q37668357 | Drug-eluting stent coatings |
Q48015888 | Drug-eluting stent in diabetes |
Q37329149 | Drug-eluting stent safety: findings from preclinical studies |
Q50944371 | Drug-eluting stent thrombosis vs bare metal stent restenosis: finding the lesser of two evils. |
Q34091036 | Drug-eluting stents |
Q45287552 | Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial |
Q37078803 | Drug-eluting stents for left main coronary artery stenosis: case selection and technical issues |
Q38653405 | Drug-eluting stents in clinical routine: a 1-year follow-up analysis based on German health insurance administrative data from 2008 to 2014. |
Q38966141 | Drug-eluting stents in patients with anterior STEMI undergoing primary angioplasty: a substudy of the DESERT cooperation. |
Q28476360 | Drug-eluting stents in patients with chronic kidney disease: a prospective registry study |
Q37577872 | Drug-eluting stents in percutaneous coronary intervention: a benefit-risk assessment |
Q37788985 | Drug-eluting stents in the elderly |
Q38262150 | Drug-eluting stents in unprotected left main coronary artery disease |
Q41836503 | Drug-eluting stents not for all patients |
Q51036741 | Drug-eluting stents versus bare metal stents following rotational atherectomy for heavily calcified coronary lesions: late angiographic and clinical follow-up results. |
Q24186681 | Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes |
Q24235466 | Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes |
Q57389444 | Drug-eluting stents versus bare-metal stents for acute coronary syndrome |
Q38612419 | Drug-eluting stents versus bare-metal stents for acute coronary syndrome. |
Q37206911 | Drug-eluting stents versus bare-metal stents for treatment of bare-metal in-stent restenosis |
Q35945466 | Drug-eluting stents: a mechanical and pharmacologic approach to coronary artery disease |
Q45190838 | Drug-eluting stents: are they really safe? |
Q50944368 | Drug-eluting stents: can we move beyond stent thrombosis? |
Q46395865 | Drug-eluting stents: is new necessarily better? |
Q45121023 | Drug-eluting stents: some bare facts |
Q38344198 | Drug-eluting stents: the past, present, and future. |
Q38162864 | Drug-eluting versus bare-metal coronary stents: where are we now? |
Q36350819 | Drug-eluting versus third-generation bare metal stents: the US strategy |
Q36040853 | Drugs to suppress cough |
Q38635747 | Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies |
Q38692636 | Dual Antiplatelet Therapy in Patients with Stable Ischemic Heart Disease |
Q40563215 | Dual antiplatelet therapy can be discontinued at three months after implantation of zotarolimus-eluting stent in patients with coronary artery disease |
Q37953153 | Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent implantation: a review of the current guidelines and literature. |
Q26830266 | Duration of dual antiplatelet treatment in the era of next generation drug-eluting stents |
Q31102731 | Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study |
Q37397071 | Early clinical outcomes of primary percutaneous coronary intervention in bharatpur, Nepal |
Q37112395 | Early restenosis after drug-eluting stent implantation: A putative role for platelet activation |
Q47696178 | Editor's note: on global informing |
Q90466540 | Editorial: Remaining issue after drug-eluting stent implantation: Histopathological mechanisms of early-phase in-stent restenosis |
Q42917980 | Effect of Coronary Target Lesion Revascularization on Late Cardiac Events After Insertion of Sirolimus-Eluting or Bare Metal Stents |
Q46701610 | Effect of Paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in Korean diabetic patients |
Q37435145 | Effect of atorvastatin-eluting stents in a rabbit iliac artery restenosis model |
Q28219713 | Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study |
Q53535880 | Effect of exercise-based cardiac rehabilitation on non-culprit mild coronary plaques in the culprit coronary artery of patients with acute coronary syndrome. |
Q30397835 | Effect of intravascular ultrasound-guided adjuvant high-pressure non-compliant balloon post-dilation after drug-eluting stent implantation |
Q84183395 | Effect of stent thrombosis on the risk-benefit balance of drug-eluting stents and bare metal stents |
Q34753360 | Effectiveness of drug-eluting stents versus bare-metal stents in large coronary arteries in patients with acute myocardial infarction |
Q28476506 | Effects of an alpha-4 integrin inhibitor on restenosis in a new porcine model combining endothelial denudation and stent placement |
Q53384415 | Effects of celecoxib on restenosis after coronary intervention and evolution of atherosclerosis (Mini-COREA) trial: celecoxib, a double-edged sword for patients with angina. |
Q34452943 | Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis |
Q46663848 | Effects of drug-eluting stents on systemic inflammatory response in patients with unstable angina pectoris undergoing percutaneous coronary intervention |
Q37413031 | Efficacies of the new paclitaxel-eluting Coroflex Please stent in percutaneous coronary intervention; comparison of efficacy between Coroflex Please and Taxus (ECO-PLEASANT) trial: study rationale and design. |
Q36688217 | Efficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial |
Q64057487 | Efficacy and safety of drug-eluting stenting compared with bypass grafting in diabetic patients with multivessel and/or left main coronary artery disease |
Q36639071 | Efficacy and safety of drug-eluting stents: current best available evidence |
Q43128990 | Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial |
Q35771807 | Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials |
Q44850925 | Efficacy of dual antiplatelet therapy combined with Naoxintong capsules [see text] following coronary microembolization induced by homologous microthrombi in rats |
Q33949407 | Efficacy of sirolimus-eluting stents compared with paclitaxel-eluting stents in an unselected population with coronary artery disease: 24-month outcomes of patients in a prospective non-randomized registry in Southern Turkey. |
Q84889727 | Emergent coronary artery bypass grafting for cardiogenic shock caused by very late drug-eluting stent thrombosis |
Q41412020 | Emodin prevents intima thickness via Wnt4/Dvl-1/β-catenin signaling pathway mediated by miR-126 in balloon-injured carotid artery rats |
Q42008887 | Endothelial cell repopulation after stenting determines in-stent neointima formation: effects of bare-metal vs. drug-eluting stents and genetic endothelial cell modification |
Q38297800 | Endothelialization of drug eluting stents and its impact on dual anti-platelet therapy duration |
Q37880131 | Endovascular management of vertebral artery disease. |
Q51345743 | Endovascular reconstruction by means of stent placement in symptomatic intracranial atherosclerotic stenosis. |
Q34373214 | Evaluating the effectiveness of a rapidly adopted cardiovascular technology with administrative data: the case of drug-eluting stents for acute coronary syndromes |
Q35230526 | Evaluation of clinical outcomes in patients undergoing dual vessel percutaneous coronary intervention using sirolimus-eluting coronary stent system in India. |
Q83014349 | Evaluation of in-stent neointimal tissue components using integrated backscatter intravascular ultrasound: comparison of drug-eluting stents and bare-metal stents |
Q36206234 | Evaluation of the efficacy of paclitaxel with curcumin combination in ovarian cancer cells |
Q37196027 | Event detection using population-based health care databases in randomized clinical trials: a novel research tool in interventional cardiology |
Q91611699 | Everolimus-Eluting Second-Generation Stents for Treatment of De Novo Lesions in Patients with Cardiac Allograft Vasculopathy |
Q24630321 | Everolimus-eluting stents in interventional cardiology |
Q42912237 | Everolimus-eluting stents: insights from the SPIRIT IV and COMPARE trials |
Q38037072 | Everolimus-eluting stents: update on current clinical studies |
Q44317798 | Evolution of stents: past, present and future |
Q46293725 | Extended follow-up following "full-metal jacket" percutaneous coronary interventions with drug-eluting stents |
Q36925442 | External adjustment sensitivity analysis for unmeasured confounding: an application to coronary stent outcomes, Pennsylvania 2004-2008. |
Q47655289 | Extracellular Matrix Proteomics Reveals Interplay of Aggrecan and Aggrecanases in Vascular Remodeling of Stented Coronary Arteries |
Q37016139 | FDA advisory panel on the safety and efficacy of drug-eluting stents: summary of findings and recommendations |
Q35049945 | Fabrication of nonbiofouling metal stent and in vitro studies on its hemocompatibility |
Q51810171 | Finite element analysis of balloon-expandable coronary stent deployment: influence of angioplasty balloon configuration. |
Q90095042 | First clinical evidence characterizing safety and efficacy of the new CoCr Biolimus-A9 eluting stent: The Biomatrix Alpha™ registry |
Q51541952 | First-in-human testing of a wirelessly controlled drug delivery microchip. |
Q45036826 | Five-year clinical follow-up of a randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus (LIPSIA Yukon trial). |
Q43685995 | Five-year clinical outcome of titanium-nitride-oxide-coated bioactive stent implantation in a real-world population: a comparison with paclitaxel-eluting stents: the PORI registry. |
Q40832041 | Five-year clinical outcomes of drug-eluting stents according to on-label and off-label use. |
Q34804267 | Fusion of 3D QCA and IVUS/OCT. |
Q45865166 | Gene therapy and stem cell therapy for cardiovascular diseases today: a model for translational research |
Q36839653 | Glucocorticoids in the prevention of restenosis after coronary angioplasty: therapeutic potential |
Q46782423 | Glucose metabolism |
Q28239975 | Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology |
Q50930160 | High frequency of contact allergy to gold in patients with endovascular coronary stents. |
Q33958472 | Highly selective and sensitive assay for paclitaxel accumulation by tumor cells based on selective solid phase extraction and micro-flow liquid chromatography coupled to mass spectrometry |
Q36261625 | Histological validation of frequency domain optical coherence tomography for the evaluation of neointimal formation after a novel polymer-free sirolimus-eluting stent implantation |
Q38235226 | Histopathology of vascular response to drug-eluting stents: an insight from human autopsy into daily practice |
Q59355879 | How and When to Decide on Revascularization in Stable Ischemic Heart Disease |
Q36441977 | How to revascularize patients with diabetes mellitus: bypass or stents and drugs? |
Q39398196 | Hydroxyapatite-polymer biocomposites for bone regeneration: A review of current trends |
Q37781241 | ISAR - A Story of Trials With Impact on Practice - |
Q40901351 | Immediate and Six-month Clinical Outcome of Percutaneous Coronary Intervention in a Tertiary Hospital in the Sultanate of Oman. |
Q47623838 | Immediate procedural and long-term clinical outcomes following drug-eluting stent implantation to ostial saphenous vein graft lesions |
Q33427823 | Impact of Anemia and Dual Antiplatelet Therapy on Mortality in Patients Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents |
Q42690175 | Impact of Paclitaxel-Eluting Balloons Compared to Second-Generation Drug-Eluting Stents for of In-Stent Restenosis in a Primarily Acute Coronary Syndrome Population |
Q47623826 | Impact of abciximab on coronary restenosis in diabetic patients undergoing elective paclitaxel-eluting stent implantation. A prospective, randomized, placebo-controlled study |
Q55057793 | Impact of body fat distribution on long-term clinical outcomes after drug-eluting stent implantation. |
Q40117934 | Impact of coronary artery calcification in percutaneous coronary intervention with paclitaxel-eluting stents: Two-year clinical outcomes of paclitaxel-eluting stents in patients from the ARRIVE program |
Q36720378 | Impact of diabetes on long-term outcome after primary angioplasty: insights from the DESERT cooperation |
Q84919676 | Impact of diabetes on long-term outcome in STEMI patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors and BMS or DES |
Q44964313 | Impact of duration of clopidogrel prescription on outcome of DES as compared to BMS in primary angioplasty: a meta-regression analysis of randomized trials |
Q50100183 | Impact of previous drug-eluting stent restenosis in non-left main coronary artery lesions on long-term outcomes after left main coronary artery stenting: an observation from the AOI-LMCA registry. |
Q51673723 | Impact of stent length on clinical outcomes of first-generation and new-generation drug-eluting stents. |
Q47228855 | Impact of vessel size, lesion length and diabetes mellitus on angiographic restenosis outcomes: insights from the NIRTOP study |
Q35773286 | Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study |
Q64119803 | Improving the anti-keloid outcomes through liposomes loading paclitaxel-cholesterol complexes |
Q83424219 | In vitro and in vivo evaluation of the safety and stability of the TAXUS Paclitaxel-Eluting Coronary Stent |
Q53233760 | In vivo evaluation of stent patency by 64-slice multidetector CT coronary angiography: shall we do it or not? |
Q44668746 | In-hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: a report from the EVENT registry |
Q37677351 | In-hospital and mid-term adverse clinical outcomes of a direct stenting strategy versus stenting after pre-dilatation for the treatment of coronary artery lesions |
Q38135896 | In-stent restenosis of drug-eluting stents. |
Q39766893 | In-stent thrombosis after 68 months of implantation inspite of continuous dual antiplatelet therapy: a case report |
Q38017707 | In-vitro dissolution methods for controlled release parenterals and their applicability to drug-eluting stent testing. |
Q45843175 | Incidence of definite stent thrombosis or in-stent restenosis after drug-eluting stent implantation for treatment of coronary in-stent restenosis: from Western Denmark Heart Registry |
Q54548046 | Incidence of periprocedural myocardial infarction following stent implantation: comparison between first- and second-generation drug-eluting stents. |
Q46695761 | Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET). |
Q48860243 | Influence of antiplatelet medications on bleeding events in hemodialysis patients. |
Q47279348 | Influence of low-dose aspirin (81 mg) on the incidence of definite stent thrombosis in patients receiving bare-metal and drug-eluting stents |
Q47804035 | Inhibition of neddylation by MLN4924 improves neointimal hyperplasia and promotes apoptosis of vascular smooth muscle cells through p53 and p62. |
Q83371544 | Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter |
Q38931805 | Inhibitory effects of roscovitine on proliferation and migration of vascular smooth muscle cells in vitro |
Q44589935 | Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a r |
Q37703974 | Interventional Revascularization of Coronary Artery Lesions in Diabetic Patients; In-hospital and One Year Follow up |
Q37108320 | Intimal hyperplasia in murine models |
Q51659927 | Intracoronary brachytherapy for in-stent restenosis: will it remain a viable therapy? |
Q37306731 | Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury |
Q39313882 | Intravascular imaging comparison of two metallic limus-eluting stents abluminally coated with biodegradable polymers: IVUS and OCT results of the DESTINY trial |
Q90479896 | Intravascular ultrasound versus angiography-guided drug-eluting stent implantation in patients with complex coronary lesions: An updated meta-analysis of nine randomized clinical trials |
Q82371928 | Intravascular ultrasound-guided primary percutaneous coronary intervention with drug-eluting stent implantation in patients with ST-segment elevation myocardial infarction |
Q39423831 | Investigation of PLLA/PCL blends and paclitaxel release profiles |
Q35584070 | Is routine stenting for acute myocardial infarction superior to balloon angioplasty? A randomised comparison in a large cohort of unselected patients |
Q44766507 | Is systematic use of drug-eluting stents justified? Arguments against |
Q36412659 | Is there an alternative to systemic anticoagulation, as related to interventional biomedical devices? |
Q43012238 | Is there any place for oral anti-restenotic treatment in the era of drug eluting stents? |
Q47586721 | Late adverse events after drug-eluting stent implantation |
Q42832154 | Late angiographic stent thrombosis of polymer based paclitaxel eluting stent |
Q47795262 | Late angiographic stent thrombosis: the LAST straw for drug-eluting stents? |
Q43937843 | Late catch-up phenomenon associated with stent fracture after sirolimus-eluting stent implantation: incidence and outcome |
Q35582676 | Late incomplete lesion coverage following Cypher stent deployment for diffuse right coronary artery stenosis |
Q34179087 | Late outcomes following percutaneous coronary interventions: results from a large, observational registry |
Q42859896 | Late stent thrombosis after drug-eluting stent implantation: a rare case of accelerated neo-atherosclerosis and early manifestation of neointimal rupture |
Q38023285 | Late stent thrombosis: the last remaining obstacle in coronary interventional therapy |
Q50859001 | Late thrombosis with drug-eluting stents: anatomy of a controversy and lessons learned. |
Q39770648 | Liposomal simvastatin attenuates neointimal hyperplasia in rats. |
Q51687284 | Local Stent-Based Release of Transforming Growth Factor-β1 Limits Arterial In-Stent Restenosis. |
Q37765610 | Local drug delivery for treatment of coronary and peripheral artery disease |
Q43835460 | Long term follow-up of drug eluting versus bare metal stents in the treatment of saphenous vein graft lesions |
Q39917344 | Long-Term Predictors of Clinical Events after Off-Label Use of Drug-Eluting Stent beyond 1 Year |
Q43282873 | Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial |
Q82071524 | Long-term (≥2 years) follow-up optical coherence tomographic study after sirolimus- and paclitaxel-eluting stent implantation: comparison to 9-month follow-up results |
Q83945566 | Long-term clinical efficacy of cutting balloon angioplasty followed by bare metal stent implantation for treating ostial left anterior descending artery lesions |
Q45082711 | Long-term clinical follow-up after drug-eluting stent implantation for bare metal in-stent restenosis. |
Q51524387 | Long-term clinical outcome of thin-strut cobalt-chromium stents in the drug-eluting stent era: results of the COBALT (comparison of bare-metal stents in all-comers' lesion treatment) registry. |
Q45409899 | Long-term clinical outcomes of drug-eluting stents vs bare-metal stents in Chinese patients. |
Q37466704 | Long-term clinical outcomes of drug-eluting stents vs. bare-metal stents in Chinese geriatric patients. |
Q26767320 | Long-term clinical outcomes of everolimus-eluting stent versus paclitaxel-eluting stent in patients undergoing percutaneous coronary interventions: a meta-analysis |
Q46942290 | Long-term follow-up after coronary stenting with the sirolimus-eluting stent in clinical practice: results from the prospective multi-center German Cypher Stent Registry |
Q34024602 | Long-term follow-up results in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents: results from a single high-volume PCI centre |
Q53074100 | Long-term outcome after drug-eluting stent implantation in comparison with bare metal stents: a single centre experience. |
Q83163597 | Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with diabetes mellitus: a patient-level meta-analysis of randomized trials |
Q51187551 | Long-term outcome of drug-eluting stenting for stenoses of the intracranial vertebrobasilar artery and vertebral ostium. |
Q37074525 | Long-term outcomes after a strategy of percutaneous coronary intervention of the infarct-related artery with drug-eluting stents or bare metal stents vs medical therapy alone in the Occluded Artery Trial (OAT). |
Q39945931 | Long-term outcomes following drug-eluting stents versus bare metal stents for primary percutaneous coronary intervention: A real-world analysis of 11,181 patients from the british columbia cardiac registry |
Q37598827 | Long-term outcomes of intravascular ultrasound-guided implantation of bare metal stents versus drug-eluting stents in primary percutaneous coronary intervention |
Q37052543 | Long-term outcomes of patients receiving drug-eluting stents |
Q33776103 | Long-term outcomes with paclitaxel-eluting stents versus bare metal stents in everyday practice: a Canadian experience |
Q37121431 | Long-term performance of the second-generation cobalt-chromium sirolimus-eluting stents in real-world clinical practice: 3-year clinical outcomes from the prospective multicenter FOCUS registry |
Q38153786 | Long-term safety of drug-eluting stents |
Q51549230 | Looking for the culprit of coronary in-stent restenosis: debatable role for the fibrinolytic system? |
Q37858604 | Low stent thrombosis risk with the XIENCE V® Everolimus-Eluting Coronary Stent: evidence from randomized and single-arm clinical trials |
Q39188081 | Low-dose paclitaxel modulates tumour fibrosis in gastric cancer |
Q56341960 | L’angioplastie du tronc commun non protégé de l’artère coronaire gauche: devenir des patients à court et moyen termes |
Q37726055 | MAD (multiagent delivery) nanolayer: delivering multiple therapeutics from hierarchically assembled surface coatings |
Q38154806 | Macroscale delivery systems for molecular and cellular payloads. |
Q38082646 | Management of cardiovascular disease in patients with kidney disease |
Q36837612 | Mechanical and Histopathological Comparison between Commercialized and Newly Designed Coronary Bare Metal Stents in a Porcine Coronary Restenosis Model |
Q83181418 | Medical and Catheter-Based Therapies for Managing Stable Coronary Disease: Lessons From the COURAGE Trial |
Q56638730 | Medikamente freisetzende Koronarstents und mit Medikamenten beschichtete Ballonkatheter |
Q46527895 | Meta-analysis shows similar risk of thrombosis after drug-eluting stent, bare-metal stent, or angioplasty |
Q34304812 | Microelectromechanical systems and nanotechnology: a platform for the next stent technological era. |
Q48097275 | Mid-to-long term mortality following surgical versus percutaneous coronary revascularization stratified according to stent subtype: An analysis of 6,682 patients with multivessel disease |
Q34167714 | Molecular imaging of drug-eluting coronary stents: method development, optimization and selected applications |
Q46277755 | Monocyte-mediated drug delivery systems for the treatment of cardiovascular diseases |
Q36779195 | Multilayered polyelectrolyte assemblies as platforms for the delivery of DNA and other nucleic acid-based therapeutics |
Q35772244 | Multiple predictors of coronary restenosis after drug-eluting stent implantation in patients with diabetes |
Q37188126 | Multivessel disease: percutaneous coronary intervention for classic coronary artery bypass grafting indications |
Q37664872 | Nanoparticle shape improves delivery: rational coarse grain molecular dynamics (rCG-MD) of taxol in worm-like PEG-PCL micelles |
Q28220309 | Nanoparticulate carriers for the treatment of coronary restenosis |
Q55265918 | Nanosecond pulsed electric fields promoting the proliferation of porcine iliac endothelial cells: An in vitro study. |
Q37844446 | Nanostructured polymer assemblies formed at interfaces: applications from immobilization and encapsulation to stimuli-responsive release |
Q37789181 | Nanotechnology and its relationship to interventional radiology. Part II: Drug Delivery, Thermotherapy, and Vascular Intervention |
Q26774540 | Neoatherosclerosis: Coronary stents seal atherosclerotic lesions but result in making a new problem of atherosclerosis |
Q44672104 | Neointimal coverage and vasodilator response to titanium-nitride-oxide-coated bioactive stents and everolimus-eluting stents in patients with acute coronary syndrome: insights from the BASE-ACS trial |
Q52643288 | Neointimal patterns obtained by optical coherence tomography correlate with specific histological components and neointimal proliferation in a swine model of restenosis. |
Q83664512 | Neointimal tissue characteristics following sirolimus-eluting stent implantation: OCT quantitative tissue property analysis |
Q45248786 | Neutropenia in patients treated with thienopyridines and high-dose oral prednisone after percutaneous coronary interventions |
Q36654375 | New developments in coronary stent technology |
Q36752088 | New percutaneous approaches for chronic total occlusion of coronary arteries |
Q36160441 | New stent design for use in small coronary arteries during percutaneous coronary intervention |
Q24642679 | Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V) |
Q45340209 | Nine-month angiographic and intravascular ultrasound outcomes after resolute zotarolimus-eluting stent implantation for the treatment of in-stent restenosis |
Q47224927 | Nine-month results of the BIOHELIX-I clinical trial study: Evaluation of the PRO-Kinetic Energy cobalt chromium bare-metal stent system. |
Q37887771 | Nitric oxide: a guardian for vascular grafts? |
Q39000577 | Nobori-Biolimus-Eluting Stents versus Resolute Zotarolimus-Eluting Stents in Patients Undergoing Coronary Intervention: A Propensity Score Matching |
Q21562470 | Non thermal irreversible electroporation: novel technology for vascular smooth muscle cells ablation |
Q24186673 | Non-acute percutaneous coronary intervention versus medical therapy in patients with ischaemic heart disease |
Q49092553 | Novel Poly(Diol Sebacate)s as Additives to Modify Paclitaxel Release From Poly(Lactic-co-Glycolic Acid) Thin Films. |
Q35997659 | Novel therapies for hemodialysis vascular access dysfunction: fact or fiction! |
Q37269384 | Off-label use of stents: bare-metal versus drug-eluting stents |
Q36614131 | Off-label use: an industry perspective on expanding use beyond approved indications |
Q46102010 | On the ability of imatinib mesylate to inhibit smooth muscle cell proliferation without delaying endothelialization: an in vitro study |
Q35820167 | On-label and off-label use of drug-eluting stents: comparison of short- and long-term outcomes |
Q35584611 | One year clinical follow up of paclitaxel eluting stents for acute myocardial infarction compared with sirolimus eluting stents |
Q39121381 | One-Year Outcome of Everolimus-Eluting Stents Versus Biolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention |
Q37387136 | One-year clinical outcomes of BioMatrix™-Biolimus A9™ eluting stent: the e-BioMatrix multicenter post marketing surveillance registry in India |
Q38052908 | One-year clinical outcomes of ultra long apollo polymer-based Paclitaxel-eluting stents in patients with complex, long coronary artery lesions |
Q44818364 | Optical coherence tomographic comparison of neointimal coverage between sirolimus- and resolute zotarolimus-eluting stents at 9 months after stent implantation. |
Q50437651 | Optical coherence tomography analysis of the stent strut and prediction of resolved strut malapposition at 3 months after 2nd-generation drug-eluting stent implantation. |
Q37851899 | Optical coherence tomography endpoints in stent clinical investigations: strut coverage |
Q54438512 | Optical coherence tomography findings of very late stent thrombosis after drug-eluting stent implantation. |
Q26852812 | Optimal Duration of Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: Shorter or Longer? |
Q38206844 | Optimal aspirin dose in acute coronary syndromes: an emerging consensus. |
Q28173975 | Optimal duration of antiplatelet therapy in recipients of coronary drug-eluting stents |
Q28217724 | Oral antiplatelet therapy and percutaneous coronary intervention |
Q37397095 | Outcome and Predictors of Stent Thrombosis in the First Romanian Registry of Drug Eluting Stent (RODESINO EXTENSION) |
Q36942534 | Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis |
Q42604179 | Outcomes of Patients Treated with the Everolimus- versus the Paclitaxel-Eluting Stents in a Consecutive Cohort of Patients at a Tertiary Medical Center |
Q46265631 | Outcomes of overlapping heterogeneous drug-eluting stents versus homogeneous drug-eluting stents for diffuse lesions in small coronary arteries |
Q35354402 | Outcomes of small coronary artery stenting with bare-metal stents versus drug-eluting stents: results from the NHLBI Dynamic Registry |
Q37077532 | Outcomes of stenting with overlapping drug-eluting stents versus overlapping drug-eluting and bare-metal stents for the treatment of diffuse coronary lesions |
Q36614116 | Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent |
Q44130145 | Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis |
Q50962970 | Paclitaxel-eluting composite fibers: drug release and tensile mechanical properties. |
Q27691306 | Paclitaxel: new uses for an old drug |
Q37878377 | Pathogenesis of implant-associated infection: the role of the host |
Q39505785 | Pathologic Etiologies of Late and Very Late Stent Thrombosis following First-Generation Drug-Eluting Stent Placement |
Q41808121 | Pathological perspective of drug-eluting stent thrombosis |
Q64938119 | Pathology of Endovascular Stents. |
Q36934746 | Pathology of atherosclerosis and stenting |
Q36126274 | Pathology of drug-eluting versus bare-metal stents in saphenous vein bypass graft lesions |
Q34268046 | Patient preferences for coronary artery bypass graft surgery or percutaneous intervention in multivessel coronary artery disease |
Q40947858 | Percutaneous coronary intervention and drug-eluting stents |
Q36752079 | Percutaneous coronary intervention for left main coronary artery disease |
Q37786640 | Percutaneous coronary intervention for small-vessel coronary disease: highlight on the everolimus-eluting stent |
Q35813673 | Percutaneous coronary intervention in diabetics |
Q34126291 | Percutaneous coronary intervention of moderate to severe calcified coronary lesions: insights from the National Heart, Lung, and Blood Institute Dynamic Registry |
Q30479477 | Percutaneous coronary intervention: recommendations for good practice and training |
Q36216817 | Percutaneous coronary revascularization in diabetics: from balloon angioplasty to drug-eluting stents |
Q46600768 | Percutaneous therapy of bifurcation lesions with drug-eluting stent implantation: the Culotte technique revisited |
Q51036735 | Percutaneous treatment of coronary bifurcations: lesion preparation before provisional bare metal stenting and subsequent immunosuppression with oral prednisone. The IMPRESS-Y study. |
Q51531976 | Performance of everolimus-eluting versus paclitaxel-eluting coronary stents in small vessels: results from the SPIRIT III and SPIRIT IV clinical trials. |
Q38084549 | Perioperative management of antiplatelet therapy in patients with drug-eluting stents. |
Q51168063 | Perivascular paclitaxel wraps block arteriovenous graft stenosis in a pig model. |
Q37756979 | Pharmacological prevention and management of restenosis |
Q30782165 | Physical characterization of alginate-Pluronic F127 gel for endoluminal NABDs delivery. |
Q40099411 | Planned versus provisional rotational atherectomy for severe calcified coronary lesions: Insights From the ROTATE multi-center registry |
Q51373459 | Plaque sealing--a concept waiting for support. |
Q45924939 | Poly(ester amide) co-polymers promote blood and tissue compatibility. |
Q45900667 | Poly-(L-lactic acid) and citric acid-crosslinked gelatin composite matrices as a drug-eluting stent coating material with endothelialization, antithrombogenic, and drug release properties. |
Q36933167 | Polyelectrolyte multilayers promote stent-mediated delivery of DNA to vascular tissue |
Q51009195 | Polymer-free versus permanent polymer drug eluting stents in coronary artery disease: A meta-analysis of 10 RCTs with 6575 patients. |
Q59110902 | Polymers for Cardiovascular Stent Coatings |
Q41486571 | Predictors of diffuse-type in-stent restenosis following drug-eluting stent implantation |
Q44570978 | Predictors of early and late target lesion revascularization after drug-eluting stent implantation |
Q44343388 | Prevalence and predictors of premature discontinuation of dual antiplatelet therapy after drug-eluting stent implantation: importance of social factors in Asian patients |
Q64105906 | Prevalence of Decreased Myocardial Blood Flow in Symptomatic Patients with Patent Coronary Stents: Insights from Low-Dose Dynamic CT Myocardial Perfusion Imaging |
Q35938663 | Preventing restenosis in early drug-eluting stent era: recent developments and future perspectives |
Q51192882 | Proceedings of the TCT: questions surround antithrombotic therapy in coronary DES implantation. |
Q35954252 | Prognostic impact of preprocedural C reactive protein levels on 6-month angiographic and 1-year clinical outcomes after drug-eluting stent implantation |
Q53570426 | Prognostic significance of asymptomatic coronary artery disease in patients with diabetes and need for early revascularization therapy. |
Q40459284 | Progression of noncalcified and calcified coronary plaque by CT angiography in SLE. |
Q92093210 | Prospective multicentre open-label randomised controlled trial of 3-month versus 12-month dual antiplatelet therapy after implantation of the new generation biodegradable polymer sirolimus TARGET-eluting coronary stent: protocol of the TARGET DAPT t |
Q35763063 | Prostate cancer and coronary heart disease: correlation or coincidence? |
Q38166727 | QCA, IVUS and OCT in interventional cardiology in 2011. |
Q45398663 | Racial differences in long-term outcomes after percutaneous coronary intervention with paclitaxel-eluting coronary stents |
Q37978664 | Radiation therapy for dialysis access stenosis: unfulfilled promise or false expectations |
Q46005297 | Randomized comparison of the Nobori biolimus A9-eluting stent with the sirolimus-eluting stent in patients with stenosis in native coronary arteries. |
Q46886141 | Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels |
Q38379261 | Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial |
Q28482627 | Rapamycin regulates the expression and activity of Krüppel-like transcription factor 2 in human umbilical vein endothelial cells |
Q28213719 | Rapid desensitization protocols for patients with cardiovascular disease and aspirin hypersensitivity in an era of dual antiplatelet therapy |
Q31119076 | Rationale and study design of the CardioGene Study: genomics of in-stent restenosis. |
Q37711403 | Real World Application of Stenting of Unprotected Left Main Coronary Stenosis: A Single-Center Experience |
Q34548825 | Real-world safety and effectiveness outcomes of a zotarolimus-eluting stent: final 3-year report of the RESOLUTE International study |
Q36273744 | Recent advances in endoluminal revascularization for intracranial atherosclerotic disease |
Q46651488 | Recurrence of in-stent restenosis in cardiac allograft vasculopathy following implantation of a sirolimus-eluting stent |
Q28537759 | Red blood cell distribution width and long-term outcome in patients undergoing percutaneous coronary intervention in the drug-eluting stenting era: a two-year cohort study |
Q39928221 | Reduction in incomplete stent apposition area caused by jailed struts after single stenting at left main bifurcation lesions: micro-CT analysis using a three-dimensional elastic bifurcated coronary artery model |
Q36354513 | Reduction of intimal hyperplasia in injured rat arteries promoted by catheter balloons coated with polyelectrolyte multilayers that contain plasmid DNA encoding PKCδ. |
Q36848895 | Release of plasmid DNA from intravascular stents coated with ultrathin multilayered polyelectrolyte films |
Q46656412 | Resistance to platelet antiaggregants: an important cause of very late thrombosis of drug eluting stents? Observations from five cases |
Q40752196 | Resistant in-stent restenosis in the drug eluting stent era. |
Q38201505 | Resolute zotarolimus-eluting coronary stent system for the treatment of coronary artery disease |
Q36486769 | Restenosis related to percutaneous coronary intervention has been solved? |
Q33791885 | Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis |
Q38201161 | Revascularization strategies for patients with stable coronary artery disease. |
Q36759494 | Review of the TAXUS Liberté SR paclitaxel-eluting coronary stent |
Q58584593 | Rhombic-Shaped Channel Stent with Enhanced Drug Capacity and Fatigue Life |
Q37260877 | Role of E2F1-cyclin E1-cyclin E2 circuit in human coronary smooth muscle cell proliferation and therapeutic potential of its downregulation by siRNAs. |
Q36433005 | Role of cAMP-phosphodiesterase 1C signaling in regulating growth factor receptor stability, vascular smooth muscle cell growth, migration, and neointimal hyperplasia |
Q35584915 | Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial). |
Q92189384 | Rotational Atherectomy: A Contemporary Appraisal |
Q33734969 | Routine Angiographic Follow-Up versus Clinical Follow-Up after Percutaneous Coronary Intervention in Acute Myocardial Infarction |
Q28539865 | Safety and efficacy of biodegradable drug-eluting vs. bare metal stents: a meta-analysis from randomized trials |
Q46529943 | Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials |
Q51189269 | Safety and efficacy with drug-eluting stent in ST-segment elevation and non-ST-segment elevation myocardial infarction. |
Q47783141 | Safety and feasibility of drug-eluting stent implantation at vertebral artery origin: the first case series in Asians |
Q57730945 | Safety of drug-coated stents |
Q37139276 | Safety of drug-eluting stents |
Q51310341 | Same or Different Drug-Eluting Stent Re-Implantation for Drug-Eluting Stent Restenosis: An Assessment Including Second-Generation Drug-Eluting Stents. |
Q43198903 | Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial |
Q43809511 | Selective drug-eluting stent implantation for high-risk patients with acute ST-elevation myocardial infarction: rationale and safety. |
Q82477429 | Serial angiographic and intravascular ultrasound evaluation to interrogate the presence of late "catch-up" phenomenon after Cypher® sirolimus-eluting stent implantation |
Q46134862 | Short and long-term benefits of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials |
Q50450276 | Short- and long-term benefits of drug-eluting stents compared to bare metal stents even in treatment for large coronary arteries. |
Q37687216 | Short- and long-term outcomes of percutaneous coronary intervention in patients with low, intermediate and high ejection fraction |
Q36897187 | Short- and long-term outcomes of single bare metal stent versus drug eluting stent in nondiabetic patients with a simple de novo lesion in the middle and large vessel |
Q47433386 | Short-term follow-up results of drug-eluting stenting in premature coronary artery disease patients with multiple atherosclerotic risk factors |
Q36335179 | Should degenerated saphenous vein grafts routinely be sealed with drug-eluting stents? |
Q37086357 | Simultaneous "hybrid" percutaneous coronary intervention and minimally invasive surgical bypass grafting: feasibility, safety, and clinical outcomes |
Q64898132 | Simultaneous stent obstruction of triple vessels with very late stent thrombosis after implantation of sirolimus-eluting stents. |
Q38970275 | Single or dual antiplatelet therapy after PCI. |
Q50941839 | Single-center randomized evaluation of paclitaxel-eluting versus conventional stent in acute myocardial infarction (SELECTION). |
Q41390902 | Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arteries. |
Q36376420 | Sirolimus- or paclitaxel-eluting stents for coronary artery revascularisation |
Q35925484 | Sirolimus- or paclitaxel-eluting stents to prevent coronary artery restenosis |
Q35784102 | Sirolimus- versus paclitaxel-eluting stents in patients with stenosis in a native coronary artery |
Q35707420 | Sirolimus-eluting dextran and polyglutamic acid hybrid coatings on AZ31 for stent applications. |
Q57916573 | Solely abluminal drug release from coronary stents could possibly improve reendothelialization |
Q82511623 | Soluble receptors for advanced glycation end products (sRAGE) as a predictor of restenosis following percutaneous coronary intervention |
Q38126880 | Stent evaluation with optical coherence tomography. |
Q45930222 | Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. |
Q90379953 | Stent thrombosis distal to the segment showing early in-stent restenosis with everolimus-eluting stent |
Q38014979 | Stent thrombosis in patients with chronic kidney disease |
Q40243361 | Stent thrombosis in real-world patients: a comparison of drug-eluting with bare metal stents |
Q52581576 | Stent thrombosis rates the first year and beyond with new- and old-generation drug-eluting stents compared to bare metal stents. |
Q37996688 | Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. |
Q40889474 | Stent underexpansion in angiographic guided percutaneous coronary intervention, despite adjunctive balloon post-dilatation, in drug eluting stent era. |
Q46496368 | Stent-based delivery of ABT-578 via a phosphorylcholine surface coating reduces neointimal formation in the porcine coronary model |
Q38729698 | Stent-induced tracheal stenosis can be predicted by IL-8 expression in rabbits. |
Q36360162 | Stents or surgery: the case for stents |
Q38979758 | Stents: Biomechanics, Biomaterials, and Insights from Computational Modeling. |
Q85455953 | Study of novel coating strategy for coronary stents: simutaneous coating of VEGF and anti- CD34 antibody |
Q51007148 | Success, safety, and efficacy of implantation of diamond-like carbon-coated stents. |
Q38262668 | Surgical versus percutaneous revascularization in patients with multivessel coronary artery disease |
Q34465141 | Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis |
Q35796636 | Systematic Review of Chinese Herbal Medicines for Preventing in-Stent Coronary Restenosis after Percutaneous Coronary Intervention |
Q51385693 | Systemic inflammation after drug-eluting stent placement. |
Q51022640 | Systemic nanoparticle paclitaxel (nab-paclitaxel) for in-stent restenosis I (SNAPIST-I): a first-in-human safety and dose-finding study. |
Q42085307 | Target lesion revascularisation in patients treated with a sirolimus-eluting or paclitaxel-eluting stent |
Q59813525 | Targeted Delivery of Bioactive Molecules for Vascular Intervention and Tissue Engineering |
Q28543965 | Targeted inhibitory effect of Lenti-SM22alpha-p27-EGFP recombinant lentiviral vectors on proliferation of vascular smooth muscle cells without compromising re-endothelialization in a rat carotid artery balloon injury model |
Q42829200 | Targeting drug-eluting stents to lesions at high risk of restenosis: a flawed approach? |
Q36321778 | Technology Insight: an overview of research in drug-eluting stents |
Q37387217 | Temporal Trends in Clinical Outcomes Following Percutaneous Coronary Intervention in Patients with Renal Insufficiency |
Q35526303 | Temporal trends in percutaneous coronary intervention outcomes among older patients in the United States |
Q36559145 | The 5-year projection on the future of interventional cardiology |
Q39465229 | The Absorb bioresorbable vascular scaffold for the treatment of coronary artery disease |
Q35998044 | The FDA Review Process for Cardiac Medical Devices in Children: A Review for the Clinician |
Q36117819 | The Food and Drug Administration and pragmatic clinical trials of marketed medical products |
Q50993393 | The Sirolimus-eluting coronary stent in daily routine practice in Germany: trends in indications over the years. Results from the prospective multi-centre German Cypher Stent Registry. |
Q34996907 | The association of diabetes mellitus with clinical outcomes after coronary stenting: a meta-analysis |
Q36405134 | The cell cycle: a critical therapeutic target to prevent vascular proliferative disease |
Q39840291 | The comparative safety of bare-metal and drug-eluting intracoronary stents |
Q36735675 | The costs and quality-of-life outcomes of drug-eluting coronary stents: a systematic review |
Q36066019 | The drug-based pipeline against restenosis |
Q35987013 | The drug-eluting stent information gap. |
Q45004975 | The e-Cypher registry: objectives and organization |
Q80275766 | The early invasive strategy revisited: FRISC II at 5 years |
Q37121773 | The economic burden of complications during percutaneous coronary intervention |
Q46527906 | The effects of vinblastine on endothelial cells |
Q34175429 | The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease |
Q38012002 | The importance of the endothelium in atherothrombosis and coronary stenting |
Q40534392 | The influence of advancing age on implantation of drug-eluting stents. |
Q50921953 | The lack of endothelization after drug-eluting stent implantation as a cause of fatal late stent thrombosis. |
Q50934202 | The paclitaxel-eluting Coroflex Please stent pilot study (PECOPS I) : the one-year clinical follow-up. |
Q37387972 | The paclitaxel-eluting PTCA-balloon in combination with a cobalt-chromium stent in two different sequences to treat de novo coronary artery lesions: an angiographic follow up study |
Q39755962 | The potential of surgical strategy for incomplete stent apposition after implantation of a sirolimus eluting stent |
Q36225762 | The power prior: theory and applications |
Q43294410 | The risk of definitive stent thrombosis is increased after "off-label" stent implantation irrespective of drug-eluting stent or bare-metal stent use. |
Q37248010 | The risks and benefits of drug-eluting stents in the setting of STEMI. |
Q36982530 | The role of CABG in the era of drug-eluting stents: a surgeon's viewpoint |
Q34720419 | The role of mitosis in LDL transport through cultured endothelial cell monolayers |
Q28200757 | The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease |
Q37362714 | The safety of drug-eluting stents |
Q36405138 | The vascular effects of cilostazol |
Q38199360 | Therapy in ST-elevation myocardial infarction: reperfusion strategies, pharmacology and stent selection. |
Q36748161 | Therapy insight: diabetes and drug-eluting stents |
Q48212416 | Third generation dual-source CT enables accurate diagnosis of coronary restenosis in all size stents with low radiation dose and preserved image quality. |
Q43842750 | Third in-stent restenosis in sirolimus eluting stents: predictors of the next restenosis |
Q40097851 | Thrombosis after stent implantation: how much of a problem is there? |
Q39787837 | Thrombosis: the last frontier of coronary stenting? |
Q38265789 | Titania nanotube arrays for local drug delivery: recent advances and perspectives |
Q54069775 | Titanium-nitride-oxIde-coated stents multicenter registry in diaBEtic patienTs: the TIBET registry. |
Q46537651 | Titanium-nitride-oxide-coated Titan-2 bioactive coronary stent: a new horizon for coronary intervention |
Q48288451 | Total sleep deprivation augments balloon angioplasty-induced neointimal hyperplasia in rats |
Q35485519 | Translational research: current status, challenges and future strategies. |
Q35771454 | Treatment of bifurcation lesions with two stents: one year angiographic and clinical follow up of crush versus T stenting |
Q43281173 | Treatment of stenoses of vertebral artery origin using short drug-eluting coronary stents: improved follow-up results |
Q47201507 | Treatment of symptomatic middle cerebral artery stenosis with balloon-mounted stents: long-term follow-up at a single center |
Q36239509 | Treatment of unprotected left main coronary artery disease with drug-eluting stents: is it time for a randomized trial? |
Q36335174 | Treatment of unprotected left main coronary artery stenosis in the drug-eluting stent era. |
Q51110906 | Trend to move from permanent metals to degradable, multifunctional polymer or metallic implants in the example of coronary stents. |
Q92153486 | Two Years Efficacy of Paclitaxel-Coated Balloon Dilation for In-Stent Renal Artery Restenosis Due to Takayasu Arteritis |
Q39459597 | Two-Year Follow-up of Sirolimus-Eluting Stents versus Paclitaxel-Eluting Stents in Acute Myocardial Infarction |
Q41018522 | Two-year clinical outcomes of the NOBORI biolimus-eluting stents versus XIENCE/PROMUS everolimus-eluting stents in small vessel disease |
Q45366439 | Two-year clinical outcomes with paclitaxel-eluting coronary stents in patients with chronic total occlusions: analysis from the TAXUS ARRIVE program |
Q51487998 | Two-year follow-up intravascular ultrasound analysis after bare metal stent implantation in 120 lesions. |
Q28073031 | Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment |
Q47133703 | Undesired Outcomes of the Catania Stent Compared to the Xience Stent in Patients Undergoing Angioplasty: A Double-Blind Randomized Controlled Trial |
Q44986882 | Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial |
Q36266053 | Update on drug-eluting coronary stents |
Q36375853 | Update on drug-eluting stents for prevention of restenosis |
Q47413643 | Update on multidetector coronary CT angiography of coronary stents: in vitro evaluation of 29 different stent types with dual-source CT. |
Q38544557 | Update on percutaneous intervention for left main coronary artery stenosis |
Q36985317 | Update on stents: recent studies on the TAXUS stent system in small vessels. |
Q38864003 | Usage patterns and 1-year outcomes with the TAXUS Liberté stent: results of the TAXUS OLYMPIA registry |
Q51252575 | Use of an audible ultrasonic flowmeter to locate deeply buried coronary arteries for off-pump coronary artery bypass grafting. |
Q50930121 | Usefulness of drug eluting stent in percutaneous coronary intervention--a single center experience in Taiwan. |
Q53971688 | Utility of drug-eluting stents in complex lesions and high-risk patients. |
Q83163572 | Utility of myocardial fractional flow reserve for prediction of restenosis following sirolimus-eluting stent implantation |
Q39335623 | Variability in utilization of drug eluting stents in United States: Insights from nationwide inpatient sample. |
Q38099516 | Vascular access in haemodialysis: strengthening the Achilles' heel |
Q84109345 | Vascular disease: Endovascular treatment of vertebral artery stenosis |
Q42339589 | Vascular pathology as a result of drug-eluting stents |
Q33598021 | Vascular response profiles following a nano polymer-free sirolimus-eluting stent implantation assessed by optical coherence tomography in a porcine model |
Q35925488 | Vascular restenosis - striving for therapy |
Q37843083 | Vascular smooth muscle cell proliferation in restenosis |
Q44288213 | Vascular, downstream, and pharmacokinetic responses to treatment with a low dose drug-coated balloon in a swine femoral artery model |
Q46669724 | Very late stent thrombosis after dual antiplatelet therapy discontinuation in a patient with a history of acute stent thrombosis |
Q30251867 | Very late stent thrombosis with second generation drug eluting stents compared to bare metal stents: Network meta-analysis of randomized primary percutaneous coronary intervention trials |
Q86257244 | Very long-term follow-up of strut apposition and tissue coverage with Biolimus A9 stents analyzed by optical coherence tomography |
Q42242546 | Vessel Size and Long-Term Outcomes After Limus-Based Drug-Eluting Stent Implantation Focusing on Medium- and Small-Diameter Vessels |
Q36335468 | Vinpocetine suppresses pathological vascular remodeling by inhibiting vascular smooth muscle cell proliferation and migration |
Q48277634 | Visit-to-visit variability of systolic blood pressure predicts all-cause mortality in patients received percutaneous coronary intervention with drug-eluting stents |
Q84982959 | What Is the Effectiveness of Drug-Eluting Stents in the Treatment of ST-Elevation Myocardial Infarction? - Should Drug-Eluting Stents Be Indicated for Patients With Acute Coronary Syndrome? (Pro) - |
Q30958774 | When are drug-eluting stents effective? A critical analysis of the presently available data |
Q53670933 | When is evidence sufficient for decision-making? A framework for understanding the pace of evidence adoption. |
Q35989916 | Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part II. |
Q43127112 | Wnt4/β-catenin signaling pathway modulates balloon-injured carotid artery restenosis via disheveled-1. |
Q37472070 | Xience V everolimus-eluting coronary stent |
Q24202652 | Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease |
Q24203974 | Xiongshao for restenosis after percutaneous coronary intervention in patients with coronary heart disease |
Q41559941 | Zotarolimus-eluting durable-polymer-coated stent versus a biolimus-eluting biodegradable-polymer-coated stent in unselected patients undergoing percutaneous coronary intervention (SORT OUT VI): a randomised non-inferiority trial |
Q58227221 | Zotarolimus-eluting stent utilization in small-vessel coronary artery disease (ZEUS) |
Q46496790 | Zotarolimus-eluting vs. sirolimus-eluting coronary stents in patients with and without acute coronary syndromes: a SORT OUT III substudy |
Q83209300 | [Acute coronary syndrome - a challenge for the cooperation between outpatient and inpatient care] |
Q85867313 | [Antithrombocytic therapy and PCI. Duration of therapy after DCB/stents/scaffolds] |
Q81565632 | [Failure in the implantation of drug eluting stents. Frequency and related factors] |
Q50933577 | [Implants for drug substance delivery]. |
Q83901875 | [New developments in drug-eluting stents] |
Q83189210 | [Revascularization of coronary artery disease in diabetes mellitus] |
Q54585506 | [Stent therapy with diabetic patients who have coronary artery disease]. |
Q34504964 | microRNAs Distinctively Regulate Vascular Smooth Muscle and Endothelial Cells: Functional Implications in Angiogenesis, Atherosclerosis, and In-Stent Restenosis |
Q53536509 | p55γ functional mimetic peptide N24 blocks vascular proliferative disorders. |
Search more.